{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:02:23Z","timestamp":1793257343959,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"am","delay-in-days":372,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence nationale de la recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"French National Cancer Institute","doi-asserted-by":"publisher","award":["INCa-DGOS-INSERM_12563"],"award-info":[{"award-number":["INCa-DGOS-INSERM_12563"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.bulcan.2021.06.005","type":"journal-article","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T08:40:59Z","timestamp":1632213659000},"page":"1170-1180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance?"],"prefix":"10.1016","volume":"108","author":[{"given":"Marius","family":"Huguet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Raimond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Kaltenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Augusto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Perrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bulcan.2021.06.005_bib0245","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/17474086.2019.1629901","article-title":"A review of chimeric antigen receptor T-cells in lymphoma","volume":"12","author":"Anderson","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"22","key":"10.1016\/j.bulcan.2021.06.005_bib0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21228620","article-title":"Engineering next-generation car-t cells for better toxicity management","volume":"21","author":"Andrea","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"6372","key":"10.1016\/j.bulcan.2021.06.005_bib0255","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan4672","article-title":"Gene therapy comes of age","volume":"359","author":"Dunbar","year":"2018","journal-title":"Science (80-)"},{"issue":"8","key":"10.1016\/j.bulcan.2021.06.005_bib0260","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41409-020-0892-7","article-title":"CAR T-cell therapy for the management of refractory\/relapsed high-grade B-cell lymphoma: a practical overview","volume":"55","author":"Mohty","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.bulcan.2021.06.005_bib0265","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/MOH.0000000000000614","article-title":"Advances in chimeric antigen receptor T cells","volume":"27","author":"Beyar-Katz","year":"2020","journal-title":"Curr Opin Hematol"},{"issue":"9","key":"10.1016\/j.bulcan.2021.06.005_bib0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12092360","article-title":"Overhauling car t cells to improve efficacy, safety and cost","volume":"12","author":"Chicaybam","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bulcan.2021.06.005_bib0275","article-title":"Chimeric antigen receptor","author":"Shpall","year":"2017","journal-title":"Nat Publ Gr"},{"issue":"August","key":"10.1016\/j.bulcan.2021.06.005_bib0280","first-page":"1","article-title":"Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies","volume":"11","author":"Siegler","year":"2020","journal-title":"Front Immunol"},{"issue":"1715536","key":"10.1016\/j.bulcan.2021.06.005_bib0285","article-title":"Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries","volume":"8","author":"Jorgensen","year":"2020","journal-title":"J Mark Access Heal Policy"},{"issue":"1","key":"10.1016\/j.bulcan.2021.06.005_bib0290","doi-asserted-by":"crossref","first-page":"29094","DOI":"10.3402\/jmahp.v3.29094","article-title":"Market access pathways for cell therapies in France","volume":"3","author":"R\u00e9muzat","year":"2015","journal-title":"J Mark Access Heal Policy"},{"key":"10.1016\/j.bulcan.2021.06.005_bib0295","series-title":"Kymriah\u00ae (Tisagenlecleucel) Lymphome diffus \u00e0 grandes cellules B - Avis de la Commission de la Transparence","first-page":"1","author":"Haute Autorit\u00e9 de sant\u00e9.","year":"2018"},{"key":"10.1016\/j.bulcan.2021.06.005_bib0300","series-title":"Kymriah\u00ae (Tisagenlecleucel) Leuc\u00e9mie aigue lymphoblastique - Avis de la Commission de la Transparence","first-page":"1","author":"Haute Autorit\u00e9 de sant\u00e9.","year":"2018"},{"key":"10.1016\/j.bulcan.2021.06.005_bib0305","series-title":"YESCARTA \u00ae (Axicabtagene ciloleucel)- Avis de la Commission de la Transparence","first-page":"1","author":"Haute Autorit\u00e9 de Sant\u00e9","year":"2018"},{"issue":"7","key":"10.1016\/j.bulcan.2021.06.005_bib0310","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djy193","article-title":"Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed\/Refractory B-cell Acute Lymphoblastic Leukemia","volume":"111","author":"Sarkar","year":"2019","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.bulcan.2021.06.005_bib0315","first-page":"105","article-title":"Cost-Effectiveness of Anri-CD19 chimeric antigen receptor T-Cell therapy in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia. A societal view","author":"Thielen","year":"2020","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.bulcan.2021.06.005_bib0320","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ijc.33254","article-title":"Comments on \u201cCost of decentralized CAR T cell production in an academic non-profit setting.\u201d","volume":"148","author":"Schmitt","year":"2021","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2021.06.005_bib0325","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ijc.33253","article-title":"Reply to: Comments on \u201cCost of decentralized CAR T cell production in an academic non-profit setting.\u201d","volume":"148","author":"Ran","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bulcan.2021.06.005_bib0330","first-page":"6","article-title":"CAR T cell therapy: newer approaches to counter resistance and cost","author":"Yadav","year":"2020","journal-title":"Heliyon"},{"issue":"32","key":"10.1016\/j.bulcan.2021.06.005_bib0335","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1200\/JCO.2018.79.3570","article-title":"What can cost-effectiveness analysis tell us about chimeric antigen receptor T-cell therapy for relapsed acute lymphoblastic leukemia?","volume":"36","author":"Flowers","year":"2018","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.bulcan.2021.06.005_bib0340","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.18.02079","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma","volume":"37","author":"Lin","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2021.06.005_bib0345","doi-asserted-by":"crossref","first-page":"e202072","DOI":"10.1001\/jamanetworkopen.2020.2072","article-title":"Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma","volume":"3","author":"Lyman","year":"2020","journal-title":"JAMA Netw open"},{"issue":"2","key":"10.1016\/j.bulcan.2021.06.005_bib0350","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jcyt.2019.01.003","article-title":"Chimeric antigen receptor\u2013T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods","volume":"21","author":"Harrison","year":"2019","journal-title":"Cytotherapy"},{"issue":"12","key":"10.1016\/j.bulcan.2021.06.005_bib0355","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1002\/ijc.33156","article-title":"Cost of decentralized CAR T-cell production in an academic nonprofit setting","volume":"147","author":"Ran","year":"2020","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1016\/j.bulcan.2021.06.005_bib0360","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1001\/jamaoncol.2018.4657","article-title":"Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy-Reply","volume":"4","author":"Hernandez","year":"2018","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2021.06.005_bib0365","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1080\/13696998.2018.1529674","article-title":"Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States","volume":"21","author":"Roth","year":"2018","journal-title":"J Med Econ"},{"key":"10.1016\/j.bulcan.2021.06.005_bib0370","series-title":"AVIS D\u2019EFFICIENCE: Kymriah\u00ae (Tisagenlecleucel) Leuc\u00e9mie aigue lymphoblastique. CEESP","author":"Haute Autorit\u00e9 de sant\u00e9.","year":"2019"},{"key":"10.1016\/j.bulcan.2021.06.005_bib0375","series-title":"AVIS D\u2019EFFICIENCE: Kymriah\u00ae (Tisagenlecleucel) Lymphome diffus \u00e0 grandes cellules B. CEESP","author":"Haute Autorit\u00e9 de sant\u00e9.","year":"2019"},{"key":"10.1016\/j.bulcan.2021.06.005_bib0380","series-title":"AVIS D\u2019EFFICIENCE: YESCARTA\u00ae (axicabtagene ciloleucel). CEESP","author":"Haute Autorit\u00e9 de sant\u00e9.","year":"2019"},{"issue":"1","key":"10.1016\/j.bulcan.2021.06.005_bib0385","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrclinonc.2017.156","article-title":"Tisagenlecleucel - The first approved CAR-T-cell therapy: Implications for payers and policy makers","volume":"15","author":"Prasad","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2021.06.005_bib0390","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyw359","article-title":"Data resource profile: The French national uniform hospital discharge data set database (PMSI)","volume":"46","author":"Boudemaghe","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.bulcan.2021.06.005_bib0395","series-title":"Campagne tarifaire et budg\u00e9taire 2019 Nouveaut\u00e9s \u00abfinancement\u00bb","author":"Agence Technique de l\u2019Information sur l\u2019Hospitalisation.","year":"2019"},{"key":"10.1016\/j.bulcan.2021.06.005_bib0400","series-title":"Campagne tarifaire et budg\u00e9taire 2020 Nouveaut\u00e9s \u00abfinancement\u00bb","first-page":"1","author":"Agence Technique de l\u2019Information sur l\u2019Hospitalisation","year":"2020"},{"issue":"2","key":"10.1016\/j.bulcan.2021.06.005_bib0405","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/ejh.13427","article-title":"Cost-effectiveness of Anti-CD19 chimeric antigen receptor T-Cell therapy in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia. A societal view","volume":"105","author":"Thielen","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bulcan.2021.06.005_bib0410","unstructured":"Raimond V, Kaltenbach E, Adam C, et al. Challenges raised by the economic evaluation of CAR-T-cell therapies. The review by the French National Authority for Health. [Submitted]. Bull Cancer."},{"issue":"2","key":"10.1016\/j.bulcan.2021.06.005_bib0415","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/bmt.2015.246","article-title":"Geographic access to hematopoietic cell transplantation services in the United States","volume":"51","author":"Delamater","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"40","key":"10.1016\/j.bulcan.2021.06.005_bib0420","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1200\/EDBK_279151","article-title":"Expanding Access to Chimeric Antigen Receptor T-Cell Therapies: Challenges and Opportunities","author":"Kansagra","year":"2020","journal-title":"Am Soc Clin Oncol Educ B"},{"issue":"2","key":"10.1016\/j.bulcan.2021.06.005_bib0425","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.bulcan.2020.01.009","article-title":"CAR-T cells in acute lymphoblastic leukemias: What's new?","volume":"107","author":"Grain","year":"2020","journal-title":"Bull Cancer"},{"issue":"3","key":"10.1016\/j.bulcan.2021.06.005_bib0430","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1245\/s10434-015-4938-9","article-title":"Is It Time to Centralize Ovarian Cancer Care in the United States?","volume":"23","author":"Cowan","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2021.06.005_bib0435","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/hec.3630","article-title":"Centralisation of acute stroke services in London: Impact evaluation using two treatment groups","volume":"27","author":"Friebel","year":"2018","journal-title":"Health Econ"},{"issue":"6","key":"10.1016\/j.bulcan.2021.06.005_bib0440","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jval.2018.12.004","article-title":"Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies?","volume":"22","author":"Barlow","year":"2019","journal-title":"Value Heal"},{"key":"10.1016\/j.bulcan.2021.06.005_bib0445","series-title":"Avis 135 \u00abAcc\u00e8s aux innovations th\u00e9rapeutiques: Enjeux \u00e9thiques\u00bb","author":"Comit\u00e9 consultatif national d\u2019\u00e9thique pour les sciences de la vie et de la sant\u00e9.","year":"2020"},{"issue":"May 2018","key":"10.1016\/j.bulcan.2021.06.005_bib0450","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.canep.2018.11.004","article-title":"Epidemiology of meningiomas. A nationwide study of surgically treated tumours on French medico-administrative data","volume":"58","author":"Champeaux","year":"2019","journal-title":"Cancer Epidemiol"},{"issue":"2","key":"10.1016\/j.bulcan.2021.06.005_bib0455","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s12325-015-0187-3","article-title":"The Cost of Thromboembolic Events in Hospitalized Patients with Breast or Prostate Cancer in France","volume":"32","author":"Scotte","year":"2015","journal-title":"Adv Ther"},{"issue":"6","key":"10.1016\/j.bulcan.2021.06.005_bib0460","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2515\/therapie\/2014057","article-title":"Chocs anaphylactiques d\u2019origine m\u00e9dicamenteuse: sous-notification et PMSI","volume":"69","author":"Asfari","year":"2014","journal-title":"Therapie"},{"issue":"4","key":"10.1016\/j.bulcan.2021.06.005_bib0465","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.respe.2017.03.132","article-title":"Concordance entre les codes de diagnostic du PMSI et les donn\u00e9es de dossiers m\u00e9dicaux pour identifier le cancer colorectal m\u00e9tastatique et les comorbidit\u00e9s associ\u00e9es chez des patients \u00e2g\u00e9s","volume":"65","author":"Gouverneur","year":"2017","journal-title":"Rev Epidemiol Sante Publique"},{"issue":"3","key":"10.1016\/j.bulcan.2021.06.005_bib0470","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/pubmed\/23.3.205","article-title":"Systematic review of discharge coding accuracy","volume":"23","author":"Campbell","year":"2001","journal-title":"J Public Health Med"},{"issue":"5 II","key":"10.1016\/j.bulcan.2021.06.005_bib0475","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1111\/j.1475-6773.2005.00444.x","article-title":"Measuring diagnoses: ICD code accuracy","volume":"40","author":"O\u2019Malley","year":"2005","journal-title":"Health Serv Res"},{"key":"10.1016\/j.bulcan.2021.06.005_bib0480","first-page":"419","article-title":"Improvement of the quality of medical databases: Data-mining-based prediction of diagnostic codes from previous patient codes","volume":"210","author":"Djennaoui","year":"2015","journal-title":"Stud Health Technol Inform"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121002599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121002599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T17:20:17Z","timestamp":1762104017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455121002599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0007455121002599"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.06.005","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance?","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}